首页> 外文期刊>BMC Cancer >Confirmatory trial of non-amputative digit preservation surgery for subungual melanoma: Japan Clinical Oncology Group study (JCOG1602, J-NAIL study protocol)
【24h】

Confirmatory trial of non-amputative digit preservation surgery for subungual melanoma: Japan Clinical Oncology Group study (JCOG1602, J-NAIL study protocol)

机译:无需手术的手指保留性黑色素瘤的确证试验:日本临床肿瘤小组研究(JCOG1602,J-NAIL研究方案)

获取原文
获取外文期刊封面目录资料

摘要

Amputation is the standard of care even for early-stage subungual melanomas (SUMs), known as nail apparatus melanoma, because the nail bed and nail matrix are close to the distal phalanx. However, a recent study demonstrated that not all patients with SUMs had histologic invasion of the underlying distal phalanx. As most SUMs occur in the thumb or big toe, amputation of either the thumb or big toe substantially interferes with activities of daily living, including poor cosmesis, loss of function, and phantom pain. Non-amputative digit preservation surgery can thus be applied in such cases without compromising patient prognosis. We are conducting a multi-institutional single-arm trial to confirm the safety and efficacy of non-amputative digit preservation surgery. We will compare our results with those reported in the Japanese Melanoma Study, in which patients underwent amputation for SUMs as a traditional standard of care. Patients aged between 20 and 80?years with stage I, II, or III without evidence of tumor invasion to the underlying distal phalanx on preoperative radiograph are included in the study. The primary endpoint is major relapse-free survival (major RFS), which does not include local recurrence as an event; secondary endpoints include overall survival, digit-preservation survival, relapse-free survival, local relapse-free survival, partial relapse-free survival, and incidence of adverse events. A total of 85 patients from 21 Japanese institutions will be recruited within 5.5?years, and the follow-up period will last at least 5?years. The Japan Clinical Oncology Group Protocol Review Committee approved this study protocol in August 2017, and patient enrollment began in November 2017. Ethical approval was obtained from each institution’s Institutional Review Board prior to patient enrollment. This is the first prospective trial to confirm the safety and efficacy of non-amputative digit preservation surgery for SUM without distant metastasis or bony invasion. The results of this trial could provide evidence to support this less-invasive surgery as a new standard of care to preserve adequately functioning digits. Registry number: UMIN000029997 . Date of Registration: 16/Nov/2017. Date of First Participant Enrollment: 12/Dec/2017.
机译:即使是早期的指甲下黑色素瘤(SUM),截肢手术也是护理的标准,因为指甲床和指甲基质都靠近指骨远端。但是,最近的一项研究表明,并非所有SUM患者都在组织学上侵犯了远端指骨。由于大多数SUM发生在拇指或大脚趾上,因此,拇指或大脚趾的截肢会严重干扰日常生活活动,包括美容不良,功能丧失和幻像痛。因此,在不损害患者预后的情况下,可以采用非截肢数字保留手术。我们正在进行一项多机构单臂试验,以确认非截肢数字保留手术的安全性和有效性。我们将把我们的结果与日本黑素瘤研究中报告的结果进行比较,在该研究中,对患者进行SUM截肢术作为传统的护理标准。该研究包括年龄在20至80岁之间的I,II或III期患者,而在术前X线片上没有肿瘤浸润到远方指骨的证据。主要终点是无复发的主要生存期(主要RFS),其中不包括局部复发。次要终点包括总体生存期,手指保留生存期,无复发生存期,局部无复发生存期,部分无复发生存期以及不良事件的发生率。将在5.5年内招募来自21个日本机构的85位患者,随访期至少持续5年。日本临床肿瘤学组方案审查委员会于2017年8月批准了该研究方案,并于2017年11月开始招募患者。患者注册之前,已从每个机构的机构审查委员会获得了伦理批准。这是第一项前瞻性试验,证实了非截肢数字保留术对SUM无远处转移或骨侵犯的安全性和有效性。该试验的结果可为支持这种微创手术提供证据,以作为保持手指正常工作的新护理标准。注册表编号:UMIN000029997。注册日期:2017年11月16日。首次参加者的注册日期:2017年12月12日。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号